|Videos|June 8, 2017

What Are Pleuromutilin Antibiotics and How Do They Work?

Thomas File, MD, MSc explains what pleuromutilin antibiotics are and how they work.

Thomas File, MD, MSc, Chair of Infectious Disease Division, Summa Health in Akron, Ohio, explains what pleuromutilin antibiotics are and how they work.

Interview Transcript (slightly modified for readability):

“Pleuromutilins are a class of antimicrobial agents that have been recently developed for systemic administration for us to treat patients with certain infections. [They] work by inhibiting protein synthesis, but [they] have a unique mechanism of action which is different than other drugs that inhibit protein synthesis such that it is going to be effective against many pathogens that are resistant to these other drugs.”

DISCLOSURES: Dr. File is a consultant and on the Scientific Advisory Boards for Achaogen; Allergan; Bayer; Cempra; The Medicine’s Company; Merck; MotifBio; Nabriva; Paratek; Zavante.


Related to this article

How The Food Safety Surveillance Infrastructure Works in the US
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
This Week's Top 5 Infectious Disease News Stories: September 12-September 18, 2026
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
Ceftriaxone Safety: Separating Signal From Risk
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.
Treatment of Latent Tuberculosis in a Trice
A retrospective study of 225 patients across Cook County Department of Health clinics found that the novel 1-month 1HP regimen (isoniazid plus rifapentine) for latent TB infection had a completion rate comparable to standard longer regimens and was well tolerated, suggesting it may be a viable shorter alternative.
Peggy Lillis Foundation Will Honor C diff Advocates at Annual Gala
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.